The biotech will add a pivotal Phase III cohort to its ongoing Phase I/II trial evaluating ATSN-201 in X-linked retinoschisis ...

Bioluminescent imaging is helping researchers better understand the effectiveness of tissue regeneration enhancers delivered to injured heart tissue by different adeno-associated virus vectors.

Beacon Therapeutics has completed the enrolment in its randomised, registrational Phase II/III VISTA trial of laru-zova.

JCR Pharmaceuticals has signed a licence agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV ...

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

Adeno-associated viruses - structure and life cycle Adeno-associated viruses (AAV) are non-pathogenic parvoviruses. The Parvoviridae family includes small, icosahedral and non-enveloped viruses whose ...

Methods and Results —We constructed an rAAV containing the LacZ gene under the transcriptional control of the cytomegalovirus (CMV) promoter (AAV CMV-LacZ). We then injected 1×10 8 infectious units ...

In the July 2 release, 4DMT explained that the 25% layoffs are part of a move to “streamline operations to offset additional ...

The Hopewell site is equipped to support clinical-stage development, process-development, and scaleup for cell and gene therapy programs.

Researchers tested a gene therapy that restored partial hearing in patients with OTOF gene mutations causing congenital ...

For instance, in 2003, Gendicine, an Ad vector carrying a Rous sarcoma virus promoter-driven p53 gene, became the world's first commercialized gene therapy drug for head and neck cancer and was the ...